Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenylmethane SCHEMBL9099741 | 0.90 | SMN1; SMN2 (0.54) | CYP1A2ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL9619529 | 0.89 | LMNA (0.56) | CYP2C9ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL10888186 | 0.88 | ALDH1A1 (0.55) | CYP2C9CYP1A2ALDH1A1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL7261261 | 0.87 | LMNA (0.54) | CYP2C9ALDH1A1SMN1; SMN2LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL27492504 | 0.87 | ALDH1A1 (0.59) | CYP2C9ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL31313 | 0.87 | GAA (0.62) | CYP2C9ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL34 | 0.87 | GAA (0.62) | CYP2C9ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL11432043 | 0.87 | GAA (0.62) | CYP2C9ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL1705904 | 0.87 | GAA (0.62) | CYP2C9ALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL5068661 | 0.87 | GAA (0.62) | CYP2C9ALDH1A1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134883-A1 | NOVEL COMPOSITIONS | ARTISAN THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469027-A2 | NOVEL COMPOSITIONS | Tulex Pharmaceuticals Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469031-A1 | LIQUID RESIN EXTENDED-RELEASE ORAL NALTREXONE FORMULATION FOR TREATING AUTISM-RELATED DISORDERS | Aardvark Therapeutics Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240366505-A1 | Liquid Resin Extended-Release Oral Naltrexone Formulation for Treating Autism-Related Disorders | Aardvark Therapeutics, Inc. (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2023147443-A2 | NOVEL COMPOSITIONS | TULEX PHARMACEUTICALS INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146983-A1 | LIQUID RESIN EXTENDED-RELEASE ORAL NALTREXONE FORMULATION FOR TREATING AUTISM-RELATED DISORDERS | Aardvark Therapeutics, Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-108191729-A | A kind of synthetic method of thiosulfonic acid esters compound | 广东工业大学 | 2018-06-22 | — | — | CN | disclosed |
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
| US-RE32196-E | PROPHYLACTIC CHEMOTHERAPY OF ALLERGIC CONDITIONS | LILLY INDUSTRIES LIMITED (GB) | 1986-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | CYP2C9 2024/4885CYP1A2 1548/4885ALDH1A1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.